The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases
The American Journal of Pathology · 2023-10 · 193 (10) · 1455-1467
DOI: 10.1016/j.ajpath.2023.06.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The American Journal of Pathology, 2023-10. Verfasst von Kishor Pant und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Hormel Institute, University of Minnesota, Austin, Minnesota. Electronic address: kpant@umn.edu. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Hormel Foundation.
Abstract (Originalsprache)
The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Hormel Institute, University of Minnesota, Austin, Minnesota. Electronic address: kpant@umn.edu.
- Laboratory of Molecular Medicine and Hepatology, Faculty of Life Science and Biotechnology, South Asian University, New Delhi, India.
- Laboratory of Immunobiotechnology, Reference Centre for Lactobacilli (CERELA), National Council of Scientific and Technological Research, San Miguel de Tucuman, Argentina; Division of Experimental Pathology, Department…
- The Hormel Institute, University of Minnesota, Austin, Minnesota; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. Electronic address: sgradilo@umn.edu.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Hormel Foundation
- National Institutes of Health
Zitieren
APA
Pant, K., Venugopal, S. K., Lorenzo Pisarello, M. J., & Gradilone, S. A. (2023). The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases. The American Journal of Pathology, 193(10), 1455-1467. https://doi.org/10.1016/j.ajpath.2023.06.007
Vancouver
Pant K, Venugopal SK, Lorenzo Pisarello MJ, Gradilone SA. The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases. The American Journal of Pathology. 2023;193(10):1455-1467. doi:10.1016/j.ajpath.2023.06.007
BibTeX
@article{Pant2023,
author = {Pant, Kishor and Venugopal, Senthil K and Lorenzo Pisarello, Maria J and Gradilone, Sergio A},
title = {The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases},
journal = {The American Journal of Pathology},
year = {2023},
volume = {193},
number = {10},
pages = {1455--1467},
doi = {10.1016/j.ajpath.2023.06.007}
}
EUVIMED